Navigation Links
Strativa's New Drug Application for Ondansetron Orally Dissolving Film Strip Accepted by FDA
Date:6/10/2009

WOODCLIFF LAKE, N.J., June 10 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for ondansetron orally dissolving film strip (ODFS). Strativa is seeking approval of ondansetron ODFS for the prevention of nausea and vomiting associated with highly- and moderately-emetogenic chemotherapy, radiotherapy and surgery.

The ODFS, a new oral formulation of ondansetron designed to rapidly dissolve on the tongue, was developed using MonoSol Rx' proprietary PharmaFilm(TM) thin film technology. In clinical studies, this formulation demonstrated bioequivalence to ondansetron orally disintegrating tablets (ODT), both with and without water. Pursuant to Prescription Drug User Fee Act (PDUFA) guidelines, Strativa expects the FDA will complete its review or otherwise respond to the NDA by the first quarter of 2010.

"We are very pleased with the acceptance of our NDA submission and look forward to cooperating with the FDA on its review," said John A. MacPhee, President, Strativa Pharmaceuticals. "We believe the quick dissolving film strip formulation of ondansetron offers a convenient and easy-to-administer option for managing nausea and vomiting associated with chemotherapy, radiotherapy and surgery."

Nausea and vomiting is a common side effect associated with chemotherapy, radiation and surgery. Left untreated, nausea and vomiting can have serious consequences such as exhaustion, dehydration and undernourishment, which can interfere with treatment and healing.

In June 2008, Strativa and MonoSol Rx entered into an exclusive licensing agreement under which Strativa acquired the U.S. commercializat
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... One of the major revolutions taking place in healthcare ... practice of using genomic and other molecular analyses to ... diagnostics—laboratory analyses that inform the practice of personalized medicine—will ... fall, AACC ,s first ever virtual conference ... field and the novel technologies driving it forward, all ...
(Date:8/1/2014)... August 1, 2014 According to ... "Biophotonics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 25.16 billion in 2013, which is ... at a CAGR of 10.4% from 2014 to 2020. ... http://www.transparencymarketresearch.com/biophotonics-market.html Increasing demand for accurate early ...
(Date:8/1/2014)... Toronto, Canada (PRWEB) August 01, 2014 ... what should it cost? This webinar will discuss how ... construction. , Join speakers Bob Allen, Senior Director ... Director of Process Engineering at Fluor Industrial Services, and ... supporting Manufacturing Asset Planning at Amgen, as they provide ...
(Date:8/1/2014)... RUTHERFORD, N.J., Aug. 1, 2014 Cambrex Corporation (NYSE: ... ended June 30, 2014. Highlights ... $61.6 million in the same period last year. , ... $11.4 million in the same period last year (see table ... 2014 sales guidance increased, excluding the impact of foreign currency, ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16
... Inc., a consulting firm,providing outcomes research and health ... announces the addition of,Anthony J. Vita, MD, MPH ... clinical,professionals. The specialized background of these two practitioners ... directly to those clients,seeking to enhance the clinical ...
... Palatin Technologies,Inc. (Amex: PTN ) will announce its ... 2007 before the open of the U.S. financial,markets. ... audio webcast,hosted by Palatin,s executive management team on November ... operations in greater detail and provide,an update on corporate ...
... SOUTH SAN FRANCISCO, Calif., Nov. 5 Exelixis,Inc. ... for the third quarter,ended September 30, 2007. ... were $26.8 million,compared to $23.5 million for the ... 2006 to 2007 was primarily due to revenue ...
Cached Biology Technology:EPI-Q, Inc. Expands Capabilities with Addition of Anthony Vita, MD, MPH and Peter Herout, PharmD 2Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 2Exelixis Announces Third Quarter 2007 Financial Results and Business Update 3Exelixis Announces Third Quarter 2007 Financial Results and Business Update 4Exelixis Announces Third Quarter 2007 Financial Results and Business Update 5Exelixis Announces Third Quarter 2007 Financial Results and Business Update 6Exelixis Announces Third Quarter 2007 Financial Results and Business Update 7Exelixis Announces Third Quarter 2007 Financial Results and Business Update 8
(Date:8/1/2014)... NY, August 1, 2014Lesbian, gay, bisexual, and transgender individuals ... same problems as some of their heterosexual and cisgendered ... often face additional physiological and legal challenges to ... advances in assisted reproduction options is presented in the ... Possibilities ," published in LGBT Health ...
(Date:8/1/2014)... eye diseases is tricky enough. Knowing what causes them ... Now, University of Iowa researchers have created the most ... human eye long associated with blinding diseases, such as ... of proteins in the choroid, which supplies blood and ... By seeing differences in the abundance of proteins in ...
(Date:8/1/2014)... Sieve elements are a key component of phloem, the ... wide range of signalling molecules. Elongated cylindrical cells are ... arranged end-to-end to form sieve tubes which in turn ... "Sieve elements are very special cells which play ... very little has been known about their differentiation," says ...
Breaking Biology News(10 mins):Advances in assisted reproduction create more options & new legal issues for LGBT couples 2A map for eye disease 2Developmental regulation of important plant phloem components discovered 2
... years, researchers have worked to develop a number of ... vaccines are not intended to prevent cancer; rather, they ... Unlike traditional chemotherapy, vaccines have relatively low toxicity and, ... these vaccines have rarely been designed to directly stimulate ...
... physics to show how our circadian clocks manage to ... , In an article appearing March 13 in the ... Federale de Lausanne demonstrate that the stability of cellular ... studies in families affected by advanced sleep phase syndrome. ...
... role in the development of the placenta, the organ that ... fetus during pregnancy, and perhaps in miscarriages. , Those ... gene in mice. In humans, this gene, when mutated, raises ... retinoblastoma. Two decades ago, it was identified as the first ...
Cached Biology News:Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 2Novel antigen-cloning technique may boost efforts to develop a melanoma vaccine 3Keeping the body in sync -- The stability of cellular clocks 2Tumor-suppressor gene is critical for placenta development 2Tumor-suppressor gene is critical for placenta development 3
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Synthetic peptide derived from an internal region ... target of rapamycin FRAP RAFT1 RAPT1). ... On Western blots it identifies the ... Human (positive control: HEK293 cell lysates). Based ...
...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Biology Products: